摘要
恩格列净是一种通过抑制肾脏近端小管上的钠-葡萄糖协同转运蛋白-2 (sodium-dependent glucose transporters 2,SGLT2)来发挥降糖作用的新型降糖药物。恩格列净还可以降低心血管疾病(cardiovascular disease,CVD)终点事件的发生率,尤其是可以降低糖尿病合并射血分数降低的心力衰竭患者的住院率和死亡率。目前,恩格列净作为一种治疗CVD的药物,在临床上受到越来越多的关注,但恩格列净在CVD中发挥作用的机制尚未明晰。本篇综述主要围绕恩格列净与心力衰竭、急性心肌梗死、高血压和心律失常等疾病的相关研究进展进行综述。
Empagliflozin is a novel hypoglycemic drug by inhibiting the sodium-dependent glucose transporters 2(SGLT2) on the proximal of renal tubules.Studies have shown that empagliflozin reduced the incidence of cardiovascular endpoint events,especially the hospitalization rate and mortality rate diabetes patients combined with reduced ejection fraction heart failure.At present,as a drug for the treatment of cardiovascular diseases(CVD),empagliflozin has attracted more and more attention in clinical practice,but the mechanism of its role in CVD remains unclear.This article mainly focuses on the research progresses of empagliflozin and cardiovascular diseases,such as heart failure,acute myocardial infarction,hypertension and arrhythmia.
作者
刘孙丽
刘晶晶
朱凯驿
任洁
Liu Sunli;Liu Jingjing;Zhu Kaiyi;Ren Jie(Department of Cardiology,Third Hospital of Shanxi Medical University,Shanxi Bethune Hospital,Shanxi Academy of Medical Sciences,Tongji Shanxi Hospital,Taiyuan 030032,Shanxi,China)
出处
《中国医学前沿杂志（电子版）》
CSCD
北大核心
2024年第1期66-71,共6页
Chinese Journal of the Frontiers of Medical Science(Electronic Version)
基金
山西省基础研究计划项目(202203021222340)
山西白求恩医院人才引进科研启动金项目(2023RC23)。
关键词
恩格列净
心血管疾病
心力衰竭
急性心肌梗死
高血压
Empagliflozin
Cardiovascular disease
Heart failure
Acute myocardial infarction
Hypertension
